The question of whether and how results from personal genetic testing will motivate behavioral changes in consumers has only begun to receive the research attention it richly deserves.
Assuming rigid control over patients’ health care and subjecting them to strict regimens without offering them a choice in the matter is frank paternalism. Moreover, proceeding with an invasive test without obtaining proper informed consent is malpractice.
Society values both the appropriate use of new technological and management innovations and the maintenance of a strong personal and therapeutic relationship between patients and physicians. The medical-home model may be able to accomplish both.
People have a social obligation to conform to the general rules of sleeping: sleep at night, in a bed, in a private place away from public view, and in proper attire.
Kyle B. Brothers, MD, PhD and Esther E. Knapp, MD, MBE
Direct-to-consumer genetic testing requires that physicians share decision making with patients, not order unnecessary tests or interventions, and refer to genetic specialists when necessary.
AMA J Ethics. 2018;20(9):E812-818. doi:
10.1001/amajethics.2018.812.
Targeted dosing to treat pediatric inflammatory bowel disease is challenging because dosing guidelines are based on data gathered from adult subjects of clinical trials. Patients’ families and health care organizations also incur high costs and must try to balance potential benefits against risks of ongoing monitoring.
AMA J Ethics. 2018;20(9):E841-848. doi:
10.1001/amajethics.2018.841.
Dr Joshua D. Safer joins Ethics Talk to discuss his article, coauthored with Rebkah Tesfamariam: “How Should a Transgender Patient’s History of Deep Vein Thrombosis and Smoking Influence Gender-Affirming Health Decision Sharing?”
Dania Pagarkar joins Ethics Talk to discuss her article, coauthored with Drs Erin Harrop and Lisa Erlanger: “How Should We Approach Body Size Diversity in Clinical Trials?”